LIVZON PHARMA(01513): The provision for asset impairment will reduce the net profit attributable to the parent company by 106 million yuan in 2024.

LIVZON PHARMA (01513) announced that in order to more truthfully, accurately, and objectively reflect the financial position as of December 31, 2024, and the operating results for the year 2024, the company conducted impairment tests on assets within the scope of consolidation as of December 31, 2024 for the company and its subsidiaries based on the prudence principle. Impairment provisions were made for assets with impairment indicators. The impairment provision made this time will reduce the net profit attributable to the parent company's shareholders in 2024 by 106 million yuan.